Patents by Inventor Sean McDonough
Sean McDonough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11958908Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: November 24, 2020Date of Patent: April 16, 2024Assignee: CRISPR THERAPEUTICS AGInventors: Bradley R. Pearse, Michael Cooke, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jacob Glanville
-
Patent number: 11572411Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: November 17, 2020Date of Patent: February 7, 2023Assignee: Magenta Therapeutics, Inc.Inventors: Bradley R. Pearse, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jonathan Philip Belk, Matthew Duncan Smith
-
Publication number: 20220249683Abstract: Provided herein are methods of depleting T cells for therapeutic uses, including administration of anti-CD2 or anti-CD5 antibody drugs conjugates (ADCs) for treatment. Provided are anti-CD2 ADCs or anti-CD5 ADCs for use as agents to treat a stem cell disorder, cancer, or autoimmune disease, among other hematological and proliferative diseases. The compositions and methods described can be used to deplete populations of CD2+ or CD5+ cells, such as CD2+ or CD5+ cancer cells or CD2+ or CD5+ immune cells, and can also be used to prepare a patient for hematopoietic stem cell transplantation or solid organ transplantation.Type: ApplicationFiled: December 3, 2021Publication date: August 11, 2022Inventors: Anthony Boitano, Michael Cooke, Sean Mcdonough, Jennifer Lynn Proctor
-
Publication number: 20210369854Abstract: The invention provides anti-CD5 antibodies, antigen-binding fragments thereof, and antibody drug conjugates thereof, for use in treating, for example, a stem cell disorder, cancer, or autoimmune disease, among other hematological and proliferative diseases. Compositions and methods for depleting populations of CD5+ cells, such as CD5+ cancer cells and CD5+ immune cells are described, and can be used to treat cancers and autoimmune diseases directly as stand-alone therapies by eradicating cancerous cells and autoreactive immune cells that express CD5 and/or to prepare a patient for hematopoietic stem cell transplantation, for instance, by depleting populations of CD5+ immune cells that cross-react with, and mount an immune response against, non-self hematopoietic stem cells.Type: ApplicationFiled: April 29, 2021Publication date: December 2, 2021Inventors: Anthony Boitano, Michael Cooke, Rahul Palchaudhuri, Sean McDonough
-
Publication number: 20210371524Abstract: Disclosed are anti-CD45 antibodies and antibody drug conjugates (ADCs) useful in therapeutic methods, including targeting CD45 expressing hematopoietic stem cells (HSCs) or immune cells prior to transplantation.Type: ApplicationFiled: April 29, 2021Publication date: December 2, 2021Inventors: Rahul Palchaudhuri, Bradley R. Pearse, Hillary Adams, Sean McDonough, Michael Cooke, Anthony Boitano
-
Publication number: 20210317228Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: November 17, 2020Publication date: October 14, 2021Inventors: Bradley R. Pearse, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jonathan Philip Belk, Matthew Duncan Smith
-
Publication number: 20210206872Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: November 24, 2020Publication date: July 8, 2021Inventors: Bradley R. Pearse, Michael Cooke, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jacob Glanville
-
Patent number: 10959687Abstract: An adapter to be used to position and restrain a patient's head movement during magnetic resonance imaging (MRI), computed tomography (CT) imaging, positron emission tomography (PET) imaging, X-ray imaging or other imaging or medical procedures. The adapter has a high degree of adjustability and modularity. The adapter can be fitted to a patient quickly and comfortably by offering translational, rotational and height adjustment during the fitting procedure, thereby reducing the overall time for the MRI. The adapter includes a base, one or more attachment members to selectively affix the base to an imaging table, a pair of upwardly extending spaced-apart supports attached to the base, a stabilizer frame rotatably attached to the pair of supports, and a locking mechanism to selectively prevent rotation of the frame attached to the pair of supports.Type: GrantFiled: July 15, 2016Date of Patent: March 30, 2021Assignee: The Regents of the University of Colorado, a body corporateInventors: Christopher Yakacki, Eric J. Losty, Sean McDonough, Aviva Abosch
-
Patent number: 10934750Abstract: A panel fastening device that is configured to move together a first frame of a first panel unit having a first glass panel mounted within the first frame and a second frame of a second panel unit having a second glass panel mounted within the second frame. The device includes a suction cup is configured to be coupled to and released from the first glass panel of the first panel unit, and a structure is configured to be pressed against and released from the second frame of the second panel unit.Type: GrantFiled: September 24, 2019Date of Patent: March 2, 2021Inventor: Sean McDonough
-
Patent number: 10899843Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: October 23, 2018Date of Patent: January 26, 2021Assignee: Magenta Therapeutics, Inc.Inventors: Bradley R. Pearse, Michael Cooke, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jacob Glanville
-
Patent number: 10882915Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: October 23, 2018Date of Patent: January 5, 2021Assignee: Magenta Therapeutics, Inc.Inventors: Bradley R. Pearse, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jonathan Philip Belk, Matthew Duncan Smith
-
Publication number: 20200276326Abstract: The invention provides anti-CD5 antibodies, antigen-binding fragments thereof, and antibody drug conjugates thereof, for use in treating, for example, a stem cell disorder, cancer, or autoimmune disease, among other hematological and proliferative diseases. Compositions and methods for depleting populations of CD5+ cells, such as CD5+ cancer cells and CD5+ immune cells are described, and can be used to treat cancers and autoimmune diseases directly as stand-alone therapies by eradicating cancerous cells and autoreactive immune cells that express CD5 and/or to prepare a patient for hematopoietic stem cell transplantation, for instance, by depleting populations of CD5+ immune cells that cross-react with, and mount an immune response against, non-self hematopoietic stem cells.Type: ApplicationFiled: April 16, 2020Publication date: September 3, 2020Inventors: Anthony Boitano, Michael Cooke, Rahul Palchaudhuri, Sean McDonough
-
Publication number: 20200095823Abstract: A panel fastening device that is configured to move together a first frame of a first panel unit having a first glass panel mounted within the first frame and a second frame of a second panel unit having a second glass panel mounted within the second frame. The device includes a suction cup is configured to be coupled to and released from the first glass panel of the first panel unit, and a structure is configured to be pressed against and released from the second frame of the second panel unit.Type: ApplicationFiled: September 24, 2019Publication date: March 26, 2020Inventor: Sean McDonough
-
Publication number: 20190153114Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: October 23, 2018Publication date: May 23, 2019Inventors: Bradley R. Pearse, Michael Cooke, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jacob Glanville
-
Publication number: 20190144558Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: October 23, 2018Publication date: May 16, 2019Inventors: Bradley R. Pearse, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jonathan Philip Belk, Matthew Duncan Smith
-
Publication number: 20160317103Abstract: An adapter to be used to position and restrain a patient's head movement during magnetic resonance imaging (MRI), computed tomography (CT) imaging, positron emission tomography (PET) imaging, X-ray imaging or other imaging or medical procedures. The adapter has a high degree of adjustability and modularity. The adapter can be fitted to a patient quickly and comfortably by offering translational, rotational and height adjustment during the fitting procedure, thereby reducing the overall time for the MRI. The adapter includes a base, one or more attachment members to selectively affix the base to an imaging table, a pair of upwardly extending spaced-apart supports attached to the base, a stabilizer frame rotatably attached to the pair of supports, and a locking mechanism to selectively prevent rotation of the frame attached to the pair of supports.Type: ApplicationFiled: July 15, 2016Publication date: November 3, 2016Inventors: Christopher Yakacki, Eric J. Losty, Sean McDonough, Aviva Abosch
-
Publication number: 20060135854Abstract: Sleep study test results and patient information gathered at remote test sites are compressed, encrypted, and transmitted to a central server for storage. A test scoring technician, at a remote site may, upon proper authentication, access the data, interpret it, and generate and store his interpretation. A physician at another remote site may also, upon proper authentication, access the data and the scorer's interpretation thereof.Type: ApplicationFiled: May 16, 2003Publication date: June 22, 2006Applicant: SleepEx Systems, Inc.Inventors: Sean McDonough, Herb Stevenson, Kevin Smith